Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
在市场动荡和不确定时期，许多投资者转向股息收益率股票。这些公司通常具有较高的自由现金流，并以高额的股息支付来奖励股东。
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.
Benzinga的读者可以通过访问分析师股票评级页面来查看分析师对他们最喜欢的股票的最新看法。交易者可以对Benzinga庞大的分析师评级数据库进行排序，包括按分析师的准确性进行排序。
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
以下是最准确的分析师对医疗保健行业三只高收益股票的评级。
Pfizer Inc. (NYSE:PFE)
辉瑞公司（纽约证券交易所代码：PFE）
Dividend Yield: 5.66%
股息收益率：5.66%
- Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating with a price target of $45 on Sept. 16. This analyst has an accuracy rate of 70%.
- Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $28 to $30 on July 31. This analyst has an accuracy rate of 78%.
- Recent News: Pfizer recently presented positive data from Phase 2 study of Ponsegromab in Patients with cancer cachexia.
- Benzinga Pro's real-time newsfeed alerted to latest PFE news.
- 坎托·菲茨杰拉德分析师路易丝·陈在9月16日重申增持评级，目标股价为45美元。该分析师的准确率为70％。
- 富国银行分析师莫希特·班萨尔维持同等权重评级，并于7月31日将目标股价从28美元上调至30美元。该分析师的准确率为78％。
- 最新消息：辉瑞最近公布了Ponsegromab在癌症恶心症患者中的2期研究的积极数据。
- Benzinga Pro的实时新闻提醒注意最新的PFE新闻。
CVS Health Corporation (NYSE:CVS)
CVS 健康公司（纽约证券交易所代码：CVS）
- Dividend Yield: 4.55%
- RBC Capital analyst Ben Hendrix reiterated an Outperform rating with a price target of $68 on Sept. 4. This analyst has an accuracy rate of 74%
- Barclays analyst Andrew Mok maintained an Equal-Weight rating and cut the price target from $65 to $63 on Aug. 8. This analyst has an accuracy rate of 79%.
- Recent News: Wednesday, Oak Street Health, a subsidiary of CVS Health, agreed to settle for $60 million following allegations that it violated the False Claims Act.
- Benzinga Pro's charting tool helped identify the trend in CVS stock.
- 股息收益率：4.55%
- 加拿大皇家银行资本分析师本·亨德里克斯在9月4日重申了跑赢大盘的评级，目标股价为68美元。这位分析师的准确率为74％
- 巴克莱分析师安德鲁·莫克维持同等权重评级，并于8月8日将目标股价从65美元下调至63美元。这位分析师的准确率为79％。
- 最新消息：周三，CVS Health的子公司橡树街健康因被指控违反《虚假索赔法》而同意以6000万美元达成和解。
- Benzinga Pro的图表工具帮助确定了CVS股票的走势。
Gilead Sciences, Inc. (NASDAQ:GILD)
吉利德科学公司（纳斯达克股票代码：GILD）
- Dividend Yield: 3.67%
- RBC Capital analyst Brian Abrahams maintained a Sector Perform rating and raised the price target from $72 to $74 on Sept. 4. This analyst has an accuracy rate of 65%.
- Needham analyst Joseph Stringer reiterated a Hold rating on Aug. 15. This analyst has an accuracy rate of 80%.
- Recent News: Gilead Sciences, last week, revealed the results of an interim analysis from a second Phase 3 trial investigating the use of the company's twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir.
- Benzinga Pro's signals feature notified of a potential breakout in GILD shares.
- 股息收益率：3.67%
- 加拿大皇家银行资本分析师布莱恩·亚伯拉罕斯维持行业表现评级，并于9月4日将目标股价从72美元上调至74美元。该分析师的准确率为65％。
- 尼德姆分析师约瑟夫·斯金格于8月15日重申了持有评级。该分析师的准确率为80％。
- 最新消息：吉利德科学上周公布了第二项三期试验的中期分析结果，该试验调查了该公司每年两次可注射的 HIV-1 衣壳抑制剂来那卡韦的使用情况。
- Benzinga Pro的信号显示GILD股票可能出现突破。
Read More:
阅读更多：
- Nvidia, Tesla Rally As Dow, S&P 500 Surge To Fresh Highs After Fed Cuts Rates: Fear Index Remains In 'Greed' Zone
- 美联储降息后，道琼斯指数、标准普尔500指数飙升至新高，英伟达、特斯拉上涨：恐惧指数仍处于 “贪婪” 区域
